~~<i id='470B9B0D5C'><strike id='470B9B0D5C'><tt id='470B9B0D5C'><pre id='470B9B0D5C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：knowledge 2025-10-01 04:10:56 - browse：67

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： New oral drug delivery patch is modeled after octopus tentacles

hotspot

entertainment

focus

Wikipedia

AdobeBiotechandlifesciencesinvestorscontinuetodrawinnewfundsevenasthebiotechstockindexesreachnewlows

WSS

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Lung cancer screening guidelines updated for cigarette smokers

6 solutions to address cancer drug shortages and others

Medicare innovation center doesn’t save money, experts say

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

DeepMind touts AlphaFold's new skills as protein folding AI models face off

explore

Wikipedia

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Infant mortality in U.S. rose last year for first time in decades: CDC

ChatGPT in medicine: STAT answers readers' burning questions

The stability of $0 premiums in Medicare Advantage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare innovation center doesn’t save money, experts say

23andMe had bad news about my health. I wish a person had delivered it

What we owe ALS patients — and why one company fell short

Virginia high school admissions case could be legal follow

IVG is promising — but it won’t replace IVF quite yet

entertainment

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

WHO recommends second malaria vaccine

Explaining an after

CDC picks Alphabet's Verily for wasterwater surveillance contract

RSV injection headlines need to be accurate for good uptake

Experts study whether long Covid risk adds up with each reinfection

focus

focus

focus

Wikipedia